REG - Novacyt S.A. - DHSC dispute update

Novacyt SAAnnouncement

16/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220616:nRSP0594Pa&default-theme=true

RNS Number : 0594P  Novacyt S.A.  16 June 2022

 

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

DHSC dispute update

 

Paris, France and Camberley, UK - 16 June 2022 - Novacyt (EURONEXT GROWTH:
ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,
announces an update on its ongoing dispute with the Department of Health and
Social Care ("DHSC").

 

On 25 April 2022, the Company was notified that the DHSC had issued a claim
against Primerdesign Ltd and Novacyt S.A. for £134.6m in relation to the
contract dispute announced by the Company on 9 April 2021 regarding its second
supply contract with the DHSC, announced on 29 September 2020.

 

On 15 June 2022, the Company filed a defence of the claim received on 25 April
2022 and a counterclaim of £81.5m against the DHSC. The value of the
counterclaim is broadly in line with the amounts previously announced by the
Company in its full year 2020 results, plus related interest.

 

The Company continues to believe it has strong grounds to defend the claim and
assert its contractual rights, including recovering outstanding sums due from
the DHSC under the counterclaim.

 

Unfortunately, the Company is unable to provide further comment at this time
but will provide further updates as appropriate and to the extent permitted to
do so.

 

The information contained within this Announcement is deemed by the Company to
constitute inside information as stipulated under Article 7 of the Market
Abuse Regulation (EU) No. 596/2014 (as amended) as it forms part of the
domestic law of the United Kingdom by virtue of the European Union
(Withdrawal) Act 2018 (as amended). Upon the publication of this Announcement
via the Regulatory Information Service, this inside information is now
considered to be in the public domain.

 

Contacts

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black / Duncan Monteith

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com
(mailto:victoria.fostermitchell@fticonsulting.com) /
Alex.Shaw@fticonsulting.com (mailto:Alex.Shaw@fticonsulting.com) /
Novacyt.group@fticonsulting.com (mailto:Novacyt.group@fticonsulting.com)

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com
(mailto:arnaud.decheffontaines@fticonsulting.com)

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an
increasing portfolio of in vitro and molecular diagnostic tests. Its core
strengths lie in diagnostics product development, commercialisation, contract
design and manufacturing. The Company's lead business units comprise of
Primerdesign and Lab21 Products, supplying an extensive range of high-quality
assays and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which include
major corporates.

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUVAARUWUNAUR